REGULATED INFORMATION 10 December 2021, 23:55 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM - 10 December 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the

NEWS RELEASE - REGULATED INFORMATION

10 December 2021, 23:55

MDxHealth Shareholder Transparency Declaration

IRVINE, CA, and HERSTAL, BELGIUM -

10 December 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"),

a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the

disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous

provisions (the "Belgian Transparency Act"), that it received the following notification.

MDxHealth was notified that the number of shares

with respect to which Scorpiaux BV can exercise voting rights passively crossed below the threshold of 3% of the outstanding shares and

voting rights of MDxHealth on 8 November 2021. Notably, it follows from the notification that 3,867,776 shares of MDxHealth, representing

2.48% of the 155,969,226 outstanding shares and voting rights of MDxHealth, are held by Scorpiaux BV. The notification states that Scorpiaux

BV is exclusively controlled by Bart Versluys.

For further information, reference is made to

the information published on MDxHealth's website (http://www.mdxhealth.com/investors/shareholder-information).

Pursuant to the Belgian Transparency Act and

the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA)

is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such

persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total

number of voting rights in the Company.

MDxHealth is a commercial-stage precision diagnostics

company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's

tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis

of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations

in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California. For more information, visit

Important information

The MDxHealth logo, MDxHealth, ConfirmMDx

and SelectMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their